查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837442

瘧疾疫苗市場按疫苗類型、最終用戶、給藥途徑、年齡層和劑量方案分類－2025-2032年全球預測

Malaria Vaccine Market by Vaccine Type, End User, Route Of Administration, Age Group, Dosage Schedule - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，瘧疾疫苗市場規模將達到 5.3096 億美元，複合年成長率為 26.51%。

主要市場統計數據
基準年 2024 8088萬美元
預計年份：2025年 1.0259億美元
預測年份：2032年 5.3096億美元
複合年成長率 (%) 26.51%

一個權威的瘧疾疫苗領域框架，將科學突破與政策路徑和實施現實聯繫起來，以支持實際決策。

全球瘧疾疫苗研發的討論正從充滿希望的實驗轉向有計劃的研發，這主要得益於免疫學的進步、新型平台技術的出現以及政策重點的轉變。近期臨床試驗的成功檢驗，而實際的免疫接種計畫也日益重視評估如何將這些疫苗整合到現有的公共衛生體系中。隨著包括研究機構、政府機構、非政府組織和私營部門在內的相關人員審查疫情應對策略，簡潔明了、基於證據且全面的資訊對於做出明智的決策至關重要。

本報告旨在清晰、客觀、以行動為導向地分析瘧疾疫苗推廣應用的科學發展軌跡、發展挑戰以及相關人員的獎勵。報告透過分析監管動態、給藥途徑、終端用戶回饋以及不同年齡層的疫苗接種策略，將實驗室突破與實際操作聯繫起來。最終，本報告旨在為領導者提供必要的背景資訊，以便他們優先考慮投資、設計試驗計畫，並協調合作夥伴，共同實現永續、可衡量的公共衛生成果。

平台創新、監管加速和供應鏈現代化如何重新定義疫苗選擇、部署策略和專案可行性

瘧疾疫苗領域正經歷一場變革時期，其特點是平台多樣化、監管法規不斷演變以及部署理念日趨完善。 mRNA和病毒載體平台正從實驗階段邁向臨床應用階段，而蛋白質次單元和結合製劑則持續展現出符合免疫規劃要求的安全性。同時，適應性測試設計和快速的監管行動縮短了從證據產生到政策制定的時間，從而能夠更快地將療效數據轉化為流行地區的實驗室應用。

同時，供應鏈和製造領域的創新正在重塑疫苗規模化生產的格局。低溫運輸解決方案、冷凍乾燥技術和分散式生產模式的進步，正在緩解過去限制疫苗普及的種種限制因素。資金籌措機制和官民合作關係也在不斷發展，以承擔疫苗部署的初期成本。總而言之，這些轉變預示著一個新時代的到來：疫苗的選擇不僅取決於其有效性，還將考慮物流、成本效益以及與不同衛生系統之間的兼容性。

了解不斷變化的關稅政策如何改變瘧疾疫苗供應鏈中的籌資策略、採購動態和本地製造優先事項

主要經濟體貿易和關稅調整引發的政策轉變正對全球醫療保健供應鏈產生複雜的影響，尤其對疫苗採購和分發計畫具有特殊意義。關稅結構的變化會改變關鍵投入品和成品疫苗的到岸成本，影響生產地點的選擇，並改變供應商和買家之間的談判動態。對於瘧疾疫苗而言，其供應鏈可能包含多個環節，例如mRNA專用脂質、病毒載體生產試劑以及填充和包裝服務，因此關稅差異可能對籌資策略和交貨時間產生重大影響。

此外，關稅調整可能會促使製造商和採購負責人尋求對沖政策風險，從而推動策略供應商多元化。在某些情況下，關稅相關的考量可能會加速某些生產活動在地化的獎勵，促進區域製造地的形成，從而降低跨境貿易摩擦的風險。此類發展也可能影響國際捐助者和國家疫苗接種計畫所使用的採購工具，迫使它們重新調整競標規範和合約條款，以維持疫苗的可負擔性和可預測性。總而言之，關稅波動提醒我們，宏觀經濟政策可能會對疫苗供應和推廣計畫等營運決策產生連鎖反應。

一個細緻的細分框架，將疫苗平台、最終用戶角色、給藥途徑、年齡層和接種方案與計畫契合度和策略重點連結起來。

將瘧疾疫苗市場細分，可以發現不同的需求和決策標準，這些因素直接影響產品開發的優先順序和專案的實施。依疫苗類型分類，市場包括結合疫苗、活病毒疫苗、mRNA疫苗、次單位疫苗和病毒載體疫苗。 mRNA疫苗市場進一步分為傳統mRNA疫苗及自擴增mRNA疫苗，病毒載體疫苗則分為腺病毒載體及MVA載體平台。按最終用戶分類，該生態系統涵蓋非政府組織、私人診所和公共免疫項目，其中公共免疫項目進一步細分為區域項目和國家項目。依給藥途徑分類，肌肉注射、口服和皮下注射對第一線醫護人員的訓練、遵從性和廢棄物管理的影響各不相同。按年齡層別分類，青少年和成人、兒童和嬰兒需要進行客製化的臨床評估和計畫設計，其中兒童群體進一步細分為學齡前兒童和學齡兒童，這反映了不同的給藥平台和知情同意機制。根據給藥方案的不同，單劑量、三劑量和兩劑量方案對後續系統、依從性策略和成本計劃造成了不同的後勤負擔。

整合這些細分維度表明，產品選擇不能孤立地進行。例如，一種劑量節省、可自我擴增的mRNA候選藥物可能對旨在最大限度減少低溫運輸壓力的國家計畫極具吸引力，但其生產規模和監管成熟度可能會對地方試驗計畫或個別診所構成障礙。同樣，一種簡化嬰幼兒用藥的口服製劑可能對推廣宣傳活動產生變革性影響。同時，一種具有強大依從性支持的三劑次次單元給藥方案可能非常適合學齡前兒童和學齡兒童的校內給藥。認知到這些跨細分領域的依賴性，有助於相關人員優先考慮投資組合，設計合適的給藥模式，並將臨床開發策略與目標最終使用者的實際情況相協調。

區域間監管準備、生產能力和供應基礎設施的差異將決定疫苗部署和規模化的方法。

醫療基礎設施、監管管道和資金籌措模式的區域差異造成了不同的推廣應用場景，這些都必須在策略規劃中加以考慮。在美洲，完善的監管機構和公私混合的醫療服務體係有利於都市區率先推廣，私人診所和慈善機構通常會主導有針對性的試驗計畫。雖然該地區的供應鏈網路能夠滿足複雜配方的需求，但偏遠和農村地區仍面臨配送挑戰，因此需要低溫運輸創新和社區參與策略。

歐洲、中東和非洲的實際情況各不相同。一些歐洲市場正在推動監管協調，而中東和非洲部分地區則面臨基礎設施的限制。在非洲，國家疫苗接種計畫在疫苗推廣計畫中扮演越來越重要的角色，區域間的生產和採購合作也日益受到重視，以減少對遠距離供應商的依賴。同時，中東地區為區域製造和物流中心提供了服務鄰近流行市場的機遇，但前提是需要對當地產能進行投資並協調監管。

在亞太地區，存在著多種因素，包括生產能力、先進的公共疫苗接種基礎設施以及大規模疫苗外交能力。雖然東南亞和南亞部分地區人口稠密有利於疫苗的推廣，但不同的監管時間表和資金籌措機制需要製定量身定做的參與策略。在所有地區，社區參與、衛生工作者培訓以及將疫苗納入現有常規免疫計劃仍然是成功實施的關鍵。

開發商、製造商、物流商和專案合作夥伴之間的跨部門合作如何影響候選方案的可行性和採用管道

領先的生物製藥和生物技術公司、學術聯盟以及專業合約服務供應商正在塑造瘧疾疫苗的研發和推廣過程。臨床開發人員正在推動各種平台技術的研發，而關於製劑穩定性、低溫運輸要求和給藥方案的策略選擇將影響專案合作夥伴對試驗性產品的接受程度。契約製造製造商和填充包裝專家正在調整生產能力，以滿足從小批量臨床用藥到大批量計劃用藥的各種需求，而物流供應商則在溫控運輸和最後一公里配送方面進行創新。

夥伴關係模式正變得更加重視交易而非策略，授權協議、聯合開發夥伴關係和技術轉移安排正在加速提升本地生產能力。非營利組織和多邊計劃仍然是重要的召集者，它們促進數據共用、早期資金籌措和示範計劃的營運支援。這些相關人員共同建構了一個生態系統，在這個生態系統中，監管要求、品質保證和真實世界證據的一致性將決定哪些候選疫苗能夠從臨床實驗試驗階段進入常規應用階段。

為平衡短期實施需求與長期創新和韌性供應鏈策略，提出切實可行的方案建議。

產業領導者應採取務實的、以投資組合為導向的方法，在短期可行性和長期技術投入之間取得平衡。他們優先投資於能夠融入現有免疫基礎設施的候選疫苗，尤其是那些穩定性好、給藥途徑簡便的疫苗，同時也支持那些能夠減少疫苗劑量並具有廣泛免疫抗原性的創新平台。同時，他們正在加快與區域製造商和合約服務供應商的合作，以避免貿易和供應鏈風險，並縮短向流行地區交付疫苗的前置作業時間。

在研發初期，我們正加強與官方免疫機構、地方專案管理人員和當地相關人員的合作，以確保專案限制因素能夠體現在測試設計和引入後評估中。我們正在投資於針對不同年齡層的接種方案和接種點量身定做的人員培訓、低溫運輸最佳化以及依從性支援機制。最後，我們正在建立一個靈活的採購框架，以適應多種產品類型和接種方案，從而能夠隨著新的臨床證據和監管指南的出現而快速調整。實施這些建議將有助於提高瘧疾疫苗在不同環境下的引入速度和永續性。

採用透明、以證據主導的方法，結合專家同儕審查的科學研究、監管訊號和營運洞察，使臨床特徵與專案實際情況相符。

本分析整合了一手和二手證據，建構了瘧疾疫苗現況的多面觀點。研究方法結合了對同行評審期刊、監管指導文件和臨床試驗註冊庫的文獻綜述，以及針對疫苗學、供應鏈管理和公共衛生計畫實施等領域專家的結構化諮詢。此外，還審查了現有免疫項目的實施後評估和營運報告（如有），以總結物流、依從性和社區接受度的經驗教訓。

本研究採用資料三角測量法來協調資訊來源之間的差異，並著重於檢驗的政策聲明、已發表的臨床終點以及已記錄的實施經驗。調查方法優先考慮資訊來源選擇的透明度和假設的記錄，分析框架將產品屬性與專案限制清晰地連結起來，以確保其具有可操作性。倫理方面的考量包括謹慎解讀臨床數據，並在證據仍在不斷湧現時避免過早提出政策建議。

平衡整合將科學進步與操作需求相結合，為永續的瘧疾疫苗實施提供切實可行的途徑。

瘧疾疫苗研發的累積趨勢是謹慎樂觀，但同時也面臨操作上的複雜性。科學進步拓寬了可行的疫苗平台選擇範圍，但成功實施取決於產品特性與最終用戶、遞送系統和當地供應鏈的實際情況相符。監管力度和新型資金籌措機制為加快實施提供了機遇，但成功的專案需要對低溫運輸物流、劑量合規性和社區信任度給予高度重視。

展望未來，最有前景的路徑在於將務實的近期選擇（選擇符合現有免疫流程的產品）與對平台技術和本地生產能力的策略性投資相結合。這樣做將使決策者能夠降低貿易政策、供應中斷和衛生系統準備變化帶來的風險，同時保留減輕瘧疾流行地區負擔的潛力。其目標是透過精心設計和永續實施的疫苗策略，將科學進步轉化為發病率和死亡率的持續下降。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 惡性瘧疾原蟲基因變異對非洲和亞洲人群疫苗效力的影響
  • 將RTS,S疫苗納入國家免疫規劃，並加強相關低溫運輸建設。
  • 針對多種瘧疾原蟲的新一代多效價瘧疾疫苗正在進行臨床試驗
  • 透過官民合作關係技術舉措加速疫苗生產能力
  • 上市後監測，以評估長期免疫力以及兒童加強免疫接種的必要性
  • 成本效益分析為全球瘧疾疫苗資助機構的籌資策略提供資訊

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 依疫苗類型分類的瘧疾疫苗市場

  • 結合疫苗
  • 減毒活疫苗
  • mRNA疫苗
    • 常規mRNA
    • 自擴增mRNA
  • 次單位疫苗
  • 病毒載體疫苗
    • 腺病毒載體
    • Mva 向量

9. 按最終用戶分類的瘧疾疫苗市場

  • NGO
  • 私人診所
  • 公共疫苗接種計劃
    • 區域項目
    • 國家計劃

第10章 依給藥途徑分類的瘧疾疫苗市場

  • 肌肉內注射
  • 口服
  • 皮下

第11章 按年齡層別分類的瘧疾疫苗市場

  • 青春期和成年期
  • 幼兒期
    • 幼稚園
    • 學齡
  • 嬰兒期

12. 依接種時間表分類的瘧疾疫苗市場

  • 1. 接種疫苗
  • 接種疫苗 3 次
  • 兩劑疫苗

第13章 瘧疾疫苗市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 瘧疾疫苗市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國瘧疾疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GlaxoSmithKline plc
    • Serum Institute of India Pvt. Ltd.
    • Bharat BIoTech International Limited
    • Sanofi SA
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Janssen Pharmaceuticals, Inc.
    • Novavax, Inc.
    • BioNTech SE
    • Moderna, Inc.
Product Code: MRR-035DA3C63710

The Malaria Vaccine Market is projected to grow by USD 530.96 million at a CAGR of 26.51% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 80.88 million
Estimated Year [2025] USD 102.59 million
Forecast Year [2032] USD 530.96 million
CAGR (%) 26.51%

An authoritative framing of the malaria vaccine environment that connects scientific breakthroughs to policy pathways and implementation realities for practical decision-making

The global discourse around malaria vaccine development has shifted from hopeful experimentation to deliberate deployment planning, driven by advances in immunology, novel platform technologies, and shifting policy priorities. Recent clinical achievements have validated multiple vaccine approaches, while real-world immunization programs are increasingly prepared to evaluate integration into existing public health architectures. As stakeholders across research institutions, government agencies, non-governmental organizations, and private providers reassess endemic control strategies, a concise, evidence-based synthesis of the landscape becomes indispensable for informed decision-making.

This introduction frames the report's purpose: to present a clear, objective, and practice-oriented examination of scientific trajectories, delivery challenges, and stakeholder incentives shaping malaria vaccine adoption. By grounding the analysis in regulatory developments, route of administration considerations, end-user readiness, and age-specific vaccination strategies, the narrative connects laboratory breakthroughs with implementation realities. Ultimately, the intent is to provide leaders with the context they need to prioritize investments, design pilot programs, and align partners around durable, measurable public health outcomes.

How platform innovation, regulatory acceleration, and supply chain modernization are jointly redefining vaccine selection, deployment strategies, and programmatic feasibility

The malaria vaccine landscape has entered a transformative phase characterized by platform diversification, regulatory evolution, and more sophisticated deployment thinking. mRNA and viral vector platforms have migrated from experimental candidates to clinically relevant contenders, while protein subunit and conjugate formulations continue to offer established safety profiles that appeal to immunization programs. In parallel, adaptive trial designs and accelerated regulatory pathways have reduced latency between evidence generation and policy consideration, enabling faster transitions from efficacy data to pilot implementation in endemic regions.

Concurrently, supply chain and manufacturing innovations are reshaping potential scale-up scenarios. Advances in cold chain solutions, lyophilization approaches, and decentralized manufacturing models are mitigating historical constraints that limited vaccine reach. Financing mechanisms and public-private partnerships are also evolving to underwrite the early costs of introduction, while community engagement strategies have become more sophisticated, reflecting lessons learned from recent mass vaccination efforts. Taken together, these shifts herald a new era in which vaccine choices will be driven not only by efficacy but also by logistics, cost-efficiency, and programmatic fit across diverse health systems.

Understanding how evolving tariff policies reshape sourcing strategies, procurement dynamics, and regional manufacturing priorities for malaria vaccine supply chains

Policy shifts originating from trade and tariff adjustments in leading economies are affecting global health supply chains in complex ways, with tangible implications for vaccine procurement and distribution planning. Changes in tariff structures can alter the landed cost of critical inputs and finished vaccine doses, influence manufacturing site selection, and shift negotiation dynamics between suppliers and procurers. For malaria vaccines, which may rely on multi-component supply chains including specialty lipids for mRNA, viral vector production reagents, and fill-finish services, tariff differentials can meaningfully affect sourcing strategies and time-to-delivery considerations.

Moreover, tariff adjustments can prompt strategic supplier diversification as manufacturers and procurers seek to hedge policy risk. In some cases, incentives to localize certain production activities have been accelerated by tariff-related considerations, promoting regional manufacturing hubs that reduce exposure to cross-border trade frictions. These developments also influence procurement instruments used by international donors and national immunization programs, which may need to recalibrate tender specifications and contract terms to maintain affordability and predictability. In aggregate, tariff changes are a reminder that macroeconomic policy levers can cascade into operational decisions on vaccine availability and rollout timelines.

A nuanced segmentation framework linking vaccine platforms, end-user roles, administration routes, age cohorts, and dosing schedules to programmatic suitability and strategic priorities

Segmenting the malaria vaccine landscape reveals differentiated needs and decision criteria that directly influence product development priorities and programmatic adoption. Based on vaccine type, the market includes conjugate vaccines, live attenuated vaccines, mRNA vaccines, subunit vaccines, and viral vector vaccines, with mRNA further differentiated into conventional mRNA and self-amplifying mRNA, and viral vectors further partitioned into adenovirus vector and MVA vector platforms; each category carries unique manufacturing, stability, and immunogenicity considerations that affect suitability for various settings. Based on end user, the ecosystem spans non-governmental organizations, private clinics, and public immunization programs, with public immunization efforts further divided into local programs and national programs, and each end-user segment exhibits distinct procurement timelines, funding modalities, and cold chain expectations. Based on route of administration, intramuscular, oral, and subcutaneous options present different training, compliance, and waste-management implications for frontline health workers. Based on age group, adolescent and adult cohorts, children, and infants require tailored clinical evaluation and program design, with the child cohort further split into preschool and school-age populations to reflect divergent delivery platforms and consent mechanisms. Based on dosage schedule, single-dose, three-dose, and two-dose regimens impose varying logistical burdens on follow-up systems, adherence strategies, and cost planning.

Integrating these segmentation axes demonstrates that product selection cannot be siloed. For example, a self-amplifying mRNA candidate that promises dose-sparing properties may be attractive for national programs seeking to minimize cold chain strain, but its manufacturing footprint and regulatory maturity may present barriers for local pilot programs or private clinics. Similarly, an oral formulation that simplifies administration for infants could transform outreach campaigns, while a three-dose subunit schedule may align better with school-based delivery for preschool and school-age children if adherence supports are robust. Recognizing these cross-cutting dependencies allows stakeholders to prioritize portfolio investments, design appropriate delivery models, and align clinical development strategies with the operational realities of targeted end users.

Regional distinctions in regulatory readiness, manufacturing capacity, and delivery infrastructure that determine tailored approaches to vaccine introduction and scale-up

Regional variation in health infrastructure, regulatory pathways, and financing models creates divergent adoption scenarios that must be accounted for in strategic planning. In the Americas, established regulatory agencies and mixed public-private delivery landscapes favor early adoption in urban settings, with private clinics and philanthropic initiatives often leading targeted pilot programs. Supply chain networks in the region can support complex formulations, but remote and rural areas still present distribution challenges that require cold chain innovation and community engagement strategies.

Europe, Middle East & Africa encompasses a broad set of realities where robust regulatory harmonization in some European markets contrasts with infrastructure constraints in parts of the Middle East and Africa. National immunization programs in Africa are increasingly central to introduction planning, and regional collaboration on manufacturing and procurement is gaining traction as a means to reduce dependency on distant suppliers. Meanwhile, the Middle East offers opportunities for regional manufacturing and logistics hubs that can serve adjacent endemic markets, contingent on investment in local capacity and regulatory alignment.

Asia-Pacific presents a heterogeneous landscape as well, with several countries demonstrating strong manufacturing capabilities, sophisticated public immunization infrastructures, and capacity for large-scale vaccine diplomacy. In Southeast Asia and parts of South Asia, dense population centers provide implementation advantages, but varied regulatory timelines and financing mechanisms necessitate tailored entry strategies. Across all regions, localized community engagement, training for health workers, and integration with existing routine immunization schedules remain central to successful introduction.

How cross-sector collaboration among developers, manufacturers, logisticians, and program partners is shaping candidate viability and introduction pathways

Leading biopharmaceutical and biotechnology organizations, academic consortia, and specialized contract service providers are all shaping the trajectory of malaria vaccine development and deployment. Clinical developers are advancing diverse platform technologies, and their strategic choices around formulation stability, cold chain requirements, and dosing regimens influence the willingness of programmatic partners to pilot and adopt products. Contract manufacturers and fill-finish specialists are adapting to the demand for flexible capacity that can support both small-scale clinical lots and larger programmatic batches, while logistics providers are innovating around temperature-controlled transport and last-mile delivery.

Partnership models have become more transactional and more strategic at once, with licensing agreements, co-development partnerships, and technology-transfer arrangements accelerating local production capabilities. Nonprofit organizations and multilateral initiatives remain critical conveners, enabling data-sharing, financing for initial introductions, and operational support for demonstration projects. Collectively, these actors are creating an ecosystem in which alignment on regulatory requirements, quality assurance, and real-world evidence generation will determine which vaccine candidates transition from trial settings into routine use.

Practical, program-aligned recommendations for balancing immediate implementation needs with long-term innovation and resilient supply chain strategies

Industry leaders should adopt a pragmatic, portfolio-oriented approach that balances near-term implementability with longer-term technological bets. Prioritize investments in candidates that align with existing immunization infrastructures, particularly those with favorable stability profiles and simple administration routes, while maintaining parallel support for innovative platforms that promise dose-sparing or broader immunogenicity. Concurrently, accelerate partnerships with regional manufacturers and contract service providers to hedge against trade and supply chain risks and to reduce lead times for delivery to endemic settings.

Strengthen engagement with public immunization authorities, local program managers, and community stakeholders early in development to incorporate programmatic constraints into trial design and post-introduction evaluations. Invest in workforce training, cold chain optimization, and adherence-support mechanisms tailored to dosage schedules and age-specific delivery points. Finally, establish flexible procurement frameworks that can accommodate multiple product types and dosing regimens, enabling swift adaptation as new clinical evidence and regulatory guidance emerge. Implementing these recommendations will enhance both the speed and sustainability of malaria vaccine adoption across diverse contexts.

A transparent, evidence-driven methodology combining peer-reviewed science, regulatory signals, and implementation insights to align clinical attributes with programmatic realities

This analysis synthesizes primary and secondary evidence to build a multidimensional view of the malaria vaccine environment. The research approach combined targeted literature review of peer-reviewed journals, regulatory guidance documents, and clinical trial registries with structured expert consultations across vaccinology, supply chain management, and public health program implementation. Where available, post-introduction evaluations and operational reports from existing immunization programs were reviewed to extract lessons on logistics, adherence, and community acceptance.

Data triangulation was used to reconcile differences across sources, and emphasis was placed on verifiable policy statements, published clinical endpoints, and documented implementation experiences. The methodology prioritized transparency in source selection and documented assumptions, and the analytical framework explicitly connected product attributes to programmatic constraints to ensure actionable relevance. Ethical considerations included the careful interpretation of clinical data and the avoidance of premature policy recommendations where evidence remains emergent.

A balanced synthesis that links scientific progress to operational imperatives and outlines the pragmatic paths toward sustainable malaria vaccine implementation

The cumulative picture of malaria vaccine development is one of cautious optimism tempered by operational complexity. Scientific advances have broadened the menu of viable vaccine platforms, but successful introduction will hinge on aligning product characteristics with the realities of end users, delivery systems, and regional supply chains. Regulatory momentum and novel financing structures create opportunities for faster uptake, yet programmatic success will require meticulous attention to cold chain logistics, dosing adherence, and community trust.

Looking ahead, the most promising pathways blend pragmatic short-term choices-favoring products that fit existing immunization workflows-with strategic investments in platform technologies and regional manufacturing capacity. By doing so, decision-makers can mitigate risks associated with trade policy, supply disruptions, and variable health system readiness, while preserving the potential for transformative impact on malaria burden in endemic regions. The objective remains clear: translate scientific progress into durable reductions in morbidity and mortality through thoughtfully designed and sustainably implemented vaccination strategies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of genetic variations of Plasmodium falciparum on vaccine efficacy across African and Asian populations
  • 5.2. Integration of RTS,S vaccine into national immunization schedules and associated cold chain enhancements
  • 5.3. Ongoing clinical trials of next-generation multivalent malaria vaccines targeting multiple Plasmodium species
  • 5.4. Public-private partnerships accelerating vaccine production capacity through technology transfer initiatives
  • 5.5. Real-world post-marketing surveillance assessing long-term immunity and booster dose requirements in children
  • 5.6. Cost-effectiveness analyses shaping procurement strategies among global funding organizations for malaria vaccines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Malaria Vaccine Market, by Vaccine Type

  • 8.1. Conjugate Vaccine
  • 8.2. Live Attenuated Vaccine
  • 8.3. Mrna Vaccine
    • 8.3.1. Conventional Mrna
    • 8.3.2. Self Amplifying Mrna
  • 8.4. Subunit Vaccine
  • 8.5. Viral Vector Vaccine
    • 8.5.1. Adenovirus Vector
    • 8.5.2. Mva Vector

9. Malaria Vaccine Market, by End User

  • 9.1. Ngos
  • 9.2. Private Clinics
  • 9.3. Public Immunization Programs
    • 9.3.1. Local Programs
    • 9.3.2. National Programs

10. Malaria Vaccine Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Malaria Vaccine Market, by Age Group

  • 11.1. Adolescent & Adult
  • 11.2. Child
    • 11.2.1. Preschool
    • 11.2.2. School Age
  • 11.3. Infant

12. Malaria Vaccine Market, by Dosage Schedule

  • 12.1. Single Dose
  • 12.2. Three Dose
  • 12.3. Two Dose

13. Malaria Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Malaria Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Malaria Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. Serum Institute of India Pvt. Ltd.
    • 16.3.3. Bharat Biotech International Limited
    • 16.3.4. Sanofi S.A.
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Janssen Pharmaceuticals, Inc.
    • 16.3.8. Novavax, Inc.
    • 16.3.9. BioNTech SE
    • 16.3.10. Moderna, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. MALARIA VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. MALARIA VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MALARIA VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MALARIA VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 335. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 336. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. ASEAN MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE,